Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Subscribe To Our Newsletter & Stay Updated